Persistent Poor Metabolic Profile in Postmenopausal Women With Ovarian Hyperandrogenism After Testosterone Level Normalization
Open Access
- 4 April 2019
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (5) , 1087-1096
Abstract
Context Data on prevalence of metabolic risk factors in hyperandrogenic postmenopausal women are limited. Also, the correlation between metabolic disorders and androgen excess in this scenario is poorly understood. Objectives We aimed to assess the prevalence of obesity, hypertension, type 2 diabetes (T2D), and dyslipidemia (DLP) in postmenopausal women with hyperandrogenism of ovarian origin before and after surgical normalization of testosterone (T) levels, as well as the impact of androgen normalization on body mass index (BMI), glucose, and lipid metabolism. Design Retrospective study. Setting Tertiary health center. Participants Twenty-four Brazilian women with postmenopausal hyperandrogenism who underwent bilateral oophorectomy between 2004 and 2014 and had histologically confirmed virilizing ovarian tumor (VOT) or ovarian hyperthecosis (OH) and T-level normalization after surgery were selected. Main Outcome Measures FSH, LH, total and calculated free T, BMI, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) serum levels were accessed before (n = 24) and 24 months after (n = 19) bilateral oophorectomy. Results At baseline, the overall prevalence rates of obesity, T2D, DLP, and hypertension were 58.3%, 83.3%, 66.7%, and 87.5%, respectively. No significant difference in prevalence was found between patients with OH and VOTs. At follow-up, FSH, LH, and total and free T levels had returned to menopausal physiologic levels, but mean BMI and mean FPG, HbA1c, LDL-C, HDL-C, and TG levels did not differ from baseline. Conclusions Postmenopausal hyperandrogenism is associated with adverse metabolic risk. Long-term normalization of testosterone levels did not improve BMI, glucose, or lipid metabolism.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (169920/2017-8)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (2014/1459789)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/17350-0)
This publication has 31 references indexed in Scilit:
- Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trialFertility and Sterility, 2010
- Extremes of Endogenous Testosterone Are Associated with Increased Risk of Incident Coronary Events in Older WomenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Higher Serum Testosterone Concentration in Older Women is Associated with Insulin Resistance, Metabolic Syndrome, and Cardiovascular DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2009
- The investigation and management of severe hyperandrogenism pre- and postmenopause: Non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metforminGynecological Endocrinology, 2008
- Insulin resistance causing severe postmenopausal hyperandrogenismInternational Journal of Gynecology & Obstetrics, 2007
- Glucose and Insulin Components of the Metabolic Syndrome Are Associated with Hyperandrogenism in Postmenopausal Women: The Atherosclerosis Risk in Communities StudyAmerican Journal of Epidemiology, 2004
- Acquired Clitoral Enlargement Diagnosis and TreatmentAnnals of the New York Academy of Sciences, 1997
- Ovarian hyperthecosis, diabetes and hirsuties in post‐menopausal womenClinical Endocrinology, 1997
- Hormonally active gynecologic tumorsSeminars in Surgical Oncology, 1990
- Classification of the types of androgenetic alopecia (common baldness) occurring in the female sexBritish Journal of Dermatology, 1977